Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment

References

• Hattinger CM, Serra M. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. Expert Opin Drug Metab Toxicol. 2015;119:1449–1463. PubMed PMID: 26095223; eng.
   Google Scholar
• Hattinger CM, Vella S, Tavanti E, et al. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics. 2016 Dec;17(18):2097–2114. PubMed PMID: 27883291; PubMed Central PMCID: PMC5558522. eng.
   Google Scholar
• Serra M, Hattinger CM. The pharmacogenomics of osteosarcoma. Pharmacogenomics J. 2017 Jan;17(1):11–20. . PubMed PMID: 27241064; eng.
   Google Scholar
• Vos HI, Coenen MJ, Guchelaar HJ, et al. The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discov Today. 2016 Nov;21(11):1775–1786. PubMed PMID: 27352631; eng.
   Google Scholar
• Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997 Oct;33(11):1725–1731. PubMed PMID: 9470825; eng.
   Google Scholar
• Picci P. Classic Osteosarcoma. In: Picci P, Manfrini M, Fabbri N, etal., editors. Atlas of musculoskeletal tumors and tumorlike lesions. Cham: Springer International Publishing: Switzerland; 2014:147–152.
   Google Scholar
• Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011 Nov;47(16):2431–2445. PubMed PMID: 21703851; eng.
   Google Scholar
• Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015;1618:2727–2736. PubMed PMID: 26512909; eng.
   Google Scholar
• Harrison DJ, Geller DS, Gill JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018 Jan;18(1):39–50. PubMed PMID: 29210294; eng.
   Google Scholar
• Hattinger CM, Fanelli M, Tavanti E, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 2015 Sep;20(3):495–514. PubMed PMID: 26021401; eng.
   Google Scholar
• Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol. 2006 Jul;28(7):418–422. PubMed PMID: 16825986; eng.
   Google Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396–1408. PubMed PMID: 27569442; PubMed Central PMCID: PMC5052459. eng.
   Google Scholar
• Piperno-Neumann S, Le Deley MC, Redini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1070–1080. PubMed PMID: 27324280; eng.
   Google Scholar
• Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015 Feb;26(2):407–414. PubMed PMID: 25421877; PubMed Central PMCID: PMC4304379. eng.
   Google Scholar
• Lieberman HB. DNA damage repair and response proteins as targets for cancer therapy. Curr Med Chem. 2008;15(4):360–367. PubMed PMID: 18288990; eng.
   Google Scholar
• Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev. 2005 Dec;31(8):603–617. PubMed PMID: 16298073; eng
   Google Scholar
• Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet. 2015;6:157. PubMed PMID: 25954303; PubMed Central PMCID: PMC4407582. eng.
   Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012 Apr 12;31(15):1869–1883. PubMed PMID: 21892204; eng.
   Google Scholar
• Cao ZH, Yin HP, Jiang N, et al. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma. Genet Mol Res. 2015 Aug 21;14(3):10145–10151. PubMed PMID: 26345951; eng.
   Google Scholar
• Ji WP, He NB. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma. Int J Clin Exp Pathol. 2015;8(1): 894–899. PubMed PMID: 25755792; PubMed Central PMCID: PMC4348835. eng.
   Google Scholar
• Sun Y, Wu Y, Li W, et al. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma. Int J Clin Exp Pathol. 2015;8(7):7905–7912. PubMed PMID: 26339355; PubMed Central PMCID: PMC4555683. eng.
   Google Scholar
• Zhang Q, Lv LY, Li BJ, et al. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma. Genet Mol Res. 2015 Sep 22;14(3):11235–11241. PubMed PMID: 26400354; eng.
   Google Scholar
• Hao T, Feng W, Zhang J, et al. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev. 2012;13(8):3821–3824. PubMed PMID: 23098477; eng.
   Google Scholar
• Wang MJ, Zhu Y, Guo XJ, et al. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma. Genet Mol Res. 2015 Sep 28;14(3):11652–11657. PubMed PMID: 26436406; eng.
   Google Scholar
• Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012 Apr 1;118(7):1856–1867. PubMed PMID: 21887680; eng.
   Google Scholar
• Obiedat H, Alrabadi N, Sultan E, et al. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. BMC Med Genet. 2018 Jul 6;19(1):112. PubMed PMID: 29980176; PubMed Central PMCID: PMC6035436. eng.
   Google Scholar
• Hattinger CM, Biason P, Iacoboni E, et al. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget. 2016 Sep 20;7(38):61970–61987. PubMed PMID: 27566557; PubMed Central PMCID: PMC5308704. eng.
   Google Scholar
• Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009 Oct;9(5):347–353. PubMed PMID: 19434073; eng.
   Google Scholar
• Goricar K, Kovac V, Jazbec J, et al. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. Cancer Epidemiol. 2015 Apr;39(2):182–188. PubMed PMID: 25592234; eng.
   Google Scholar
• Biason P, Hattinger CM, Innocenti F, et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J. 2012 Dec;12(6):476–483. PubMed PMID: 21826087; PubMed Central PMCID: PMC3935514. eng.
   Google Scholar
• Yang LM, Li XH, Bao CF. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev. 2012;13(11): 5883–5886. PubMed PMID: 23317281; eng.
   Google Scholar
• Sun XH, Hou WG, Zhao HX, et al. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pac J Cancer Prev. 2013;14(3):2049–2052. PubMed PMID: 23679317; eng.
   Google Scholar
• Hagleitner MM, Coenen MJ, Gelderblom H, et al. A first step toward personalized medicine in osteosarcoma: pharmacogenetics as predictive marker of outcome after chemotherapy-based treatment. Clin Cancer Res. 2015 Aug 1;21(15):3436–3441. PubMed PMID: 25829401; eng.
   Google Scholar
• Bai SB, Chen HX, Bao YX, et al. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma. Asian Pac J Cancer Prev. 2013;14(6):3677–3680. PubMed PMID: 23886164; eng.
   Google Scholar
• Liu ZF, Asila AL, Aikenmu K, et al. Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma. Genet Mol Res. 2015 Oct 21;14(4):12967–12972. PubMed PMID: 26505449; eng.
   Google Scholar
• Zhao YL, Yang LB, Geng XL, et al. The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma. Pak J Med Sci. 2013 Sep;29(5):1225–1229. PubMed PMID: 24353725; PubMed Central PMCID: PMC3858920. eng.
   Google Scholar
• Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics. 2010 Aug;20(8):507–515. . PubMed PMID: 20577141; eng.
   Google Scholar
• Zhang SL, Mao NF, Sun JY, et al. Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy. Asian Pac J Cancer Prev. 2012;13(6):2705–2709. PubMed PMID: 22938445; eng.
   Google Scholar
• Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639–643. PubMed PMID: 11081456; eng.
   Google Scholar
• Teng JW, Yang ZM, Li J, et al. Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pak J Med Sci. 2013 Sep;29(5):1182–1186. PubMed PMID: 24353716; PubMed Central PMCID: PMC3858940. eng.
   Google Scholar
• Li JZ, Tian ZQ, Jiang SN, et al. Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy. Genet Mol Res. 2014 Apr 25;13(2):3186–3192. PubMed PMID: 24841650; eng.
   Google Scholar
• Liu S, Yi Z, Ling M, et al. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy. Tumour Biol. 2014 Oct;35(10):9897–9904. PubMed PMID: 24996541; eng.
   Google Scholar
• Burger H, Loos WJ, Eechoute K, et al. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011 Feb;14(1):22–34. PubMed PMID: 21251871; eng.
   Google Scholar
• Xiaohui S, Aiguo L, Xiaolin G, et al. Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy. Pak J Med Sci. 2014 Jul;30(4):886–890. PubMed PMID: 25097538; PubMed Central PMCID: PMC4121719. eng.
   Google Scholar
• Yang J, Wang ZG, Cai HQ, et al. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev. 2013;14(8):4595–4598. PubMed PMID: 24083708; eng.
   Google Scholar
• Caronia D, Patino-Garcia A, Perez-Martinez A, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6(10):e26091. PubMed PMID: 22016816; PubMed Central PMCID: PMC3189235. eng.
   Google Scholar
• Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007 Feb 15;7:10. PubMed PMID: 17302989; PubMed Central PMCID: PMC1810543. eng.
   Google Scholar
• Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014 Apr 1;14:45.
   Google Scholar
• Li J, Liu S, Wang W, et al. ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol. 2014 Oct;35(10):10129–10136. PubMed PMID: 25023406; eng.
   Google Scholar
• Liu X, Zhang Z, Deng C, et al. Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis. Oncotarget. 2017 Sep 22;8(37):62769–62779. PubMed PMID: 28977987; PubMed Central PMCID: PMC5617547. eng.
   Google Scholar
• Zhang H, Ge J, Hong H, et al. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis. World J Surg Oncol. 2017 Apr 7;15(1):75. PubMed PMID: 28388903; PubMed Central PMCID: PMC5383995. eng.
   Google Scholar
• Lan J, Yang Q, Zhou M, et al. A meta-analysis of association between glutathione S-transferase gene polymorphism and osteosarcoma chemosensitivity in Chinese population. J Cancer Res Ther. 2016 Oct;12(Supplement):64–67. PubMed PMID: 27721257; eng.
   Google Scholar
• Pu F, Chen F, Chen S, et al. Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis. Onco Targets Ther. 2015;8:1835–1842. PubMed PMID: 26229491; PubMed Central PMCID: PMC4516196. eng.
   Google Scholar
• Wang Z, Xu H, He M, et al. The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis. Eur J Cancer Care (Engl). 2015 May;24(3):417–424. PubMed PMID: 24689813; eng.
   Google Scholar
• Chen X, Jiang M, Zhao RK, et al. Quantitative assessment of the association between ABC polymorphisms and osteosarcoma response: a meta-analysis. Asian Pac J Cancer Prev. 2015;16(11):4659–4664. PubMed PMID: 26107220; eng.
   Google Scholar
• Gao R, Reece K, Sissung T, et al. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res. 2011 Mar 15;708(1–2):21–27. PubMed PMID: 21315089; PubMed Central PMCID: PMC3057957. eng.
   Google Scholar
• Blasiak J. DNA-damaging anticancer drugs - a perspective for DNA repair- oriented therapy. Curr Med Chem. 2017;2415:1488–1503. PubMed PMID: 28120709; eng.
   Google Scholar
• Koster R, Panagiotou OA, Wheeler WA, et al. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer. 2018 Apr 15;142(8):1594–1601. PubMed PMID: 29210060; PubMed Central PMCID: PMC5814322. eng.
   Google Scholar
• Mirabello L, Koster R, Moriarity BS, et al. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov. 2015 Sep;5(9):920–931. PubMed PMID: 26084801; PubMed Central PMCID: PMC4560660. eng.
   Google Scholar
• Savage SA, Mirabello L, Wang Z, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013 Jul;45(7):799–803. PubMed PMID: 23727862; PubMed Central PMCID: PMC3910497. eng.
   Google Scholar
• Ballinger ML, Goode DL, Ray-Coquard I, et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016 Sep;17(9):1261–1271. PubMed PMID: 27498913; eng.
   Google Scholar
• Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015 Dec 10;373(24):2336–2346. PubMed PMID: 26580448; PubMed Central PMCID: PMC4734119. eng.
   Google Scholar
• Ferraiuolo M, Pulito C, Finch-Edmondson M, et al. Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. Cancer Lett. 2018 Oct 1;433:18–32. PubMed PMID: 29933048; eng.
   Google Scholar
• Sun Y, Zhao J, Ji Z. Bifunctional platinum(II) complexes with bisphosphonates substituted diamine derivatives: synthesis and in vitro cytotoxicity. Chem Biodivers. 2017 Dec;14(12). PubMed PMID: 28975737; eng. doi:10.1002/cbdv.201700348
   Google Scholar
• Zhang Z, Zhu Z, Luo C, et al. A potential bone-targeting hypotoxic platinum(II) complex with an unusual cytostatic mechanism toward osteosarcoma cells. Inorg Chem. 2018 Mar 19;57(6):3315–3322. PubMed PMID: 29513007; eng.
   Google Scholar
• Ruiz MC, Resasco A, Di Virgilio AL, et al. In vitro and in vivo anticancer effects of two quinoline-platinum(II) complexes on human osteosarcoma models. Cancer Chemother Pharmacol. 2019 Jan 19 PubMed PMID: 30661096; eng. doi:10.1007/s00280-019-03773-x.
   Google Scholar
• Eskandari A, Kundu A, Lu C, et al. Synthesis, characterization, and cytotoxic properties of mono- and di-nuclear cobalt(ii)-polypyridyl complexes. Dalton Trans. 2018 Apr 24;47(16):5755–5763. PubMed PMID: 29634060; eng.
   Google Scholar